A Mono-center Study in Healthy Volunteers on the Comparative Bioavailability of Pletal 100 mg Tablets and a New Pletal 100 mg Orodispersible Tablet (ODT), This Latter in Fasting Conditions With and Without Water and Under Fed Conditions

Inclusion Criteria: 1. healthy male and female subjects of Caucasian race 2. able to read, to write and to fully understand German language 3. having given voluntary written informed consent before first invasive screening examination procedure 4. aged 18 to 45 years, inclusive 5. BMI of 18 - 28 kg/m2 6. good health as determined by medical history, physical examination, vital signs, electrocardiogram (ECG, serum/urine biochemistry and hematology) Exclusion Criteria: 1. clinically relevant allergy (except for untreated, asymptomatic, seasonal allergies at time of dosing) drug hypersensitivity 2. known hypersensitivity to one of the IMP substances 3. severe digestive disorder or surgery of the digestive tract (except for appen¬dectomy) 4. clinically relevant renal disorders (albuminuria, chronic infections) 5. clinically relevant hepatic disorders 6. clinically relevant respiratory disorders 7. clinically relevant cardiovascular disorders, especially any history of ventricular tachycardia, ventricular fibrillation or multifocal ventricular ectopics, or a history of additional risk factors for torsades de pointes (TdP) (e.g. heart failure, hypokalemia, congenital long QT-syndrome) 8. diabetes mellitus and thyroid dysfunction or other endocrine disorders 9. malignancy 10. substance abuse or addiction (alcohol, illicit drugs) in the past 3 years 11. neurologic or psychiatric illness 12. known predisposition to bleeding (e.g. active peptic ulceration, recent (within 6 month) haemorrhagic stroke, surgery within the previous three months, proliferative diabetic retinopathy, poorly controlled hypertension)